Item 7.01 Regulation FD Disclosure.

On July 27, 2022, Iain Stuart, Ph.D., Chief Scientific Officer of VYNE Therapeutics Inc., will present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference. Dr. Stuart will reference the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K during his discussion.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

The following exhibit is being furnished herewith.

Exhibit No. Description



              Presentation for B&T Cell-Mediated Autoimmune Disease Drug Development
  99.1      Conference

            Cover Page Interactive Data File (embedded within the Inline XBRL
104         document)

© Edgar Online, source Glimpses